allocetra — Topline data
Q2 2027
Expected to commence a global Phase 2b trial in knee OA with first patient dosed mid 2026 and topline data expected at Q2 and Q3 2027 supporting a pivotal Phase 3 study and potential partnership.Source filing
ENLV biotech catalysts & pipeline
ENLIVEX LTD · Data as of 2026-09-08
Upcoming catalysts
Allocetra™ — Topline data
Q2 2027
The Company previously announced the dosing of the first patient in the U.S. clinical site and believes that top-line data from this clinical trial will be available by the end of the second quarter of 2027.Source filing